PTHS

Pelthos Therapeutics Inc.
CAPPED RATING

Pelthos Therapeutics Inc. (PTHS) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (D). The rating has held at C+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
A-
Factor Score 4.0 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 75.6%
Price Return 3M -71.3%
Price Return 12M -80.1%
Catalyst Signal 0.00
Market Cap $29.3M
TTM Revenue $43.3M
Price / Sales 0.7
ROE N/A

Historical Factor Score Progression

Held C+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) A- (4.0) C+ (2.5) D (1.2) C+ (2.6) C+ (2.7)
2026-11-07 B- (3.0) A (4.2) C+ (2.5) D (1.3) C+ (2.7) C+ (2.7)
2026-10-31 B- (3.0) A- (4.1) C+ (2.5) D (1.4) C+ (2.7) C+ (2.7)
2026-10-24 B- (3.0) A- (4.1) C+ (2.5) D+ (1.8) C+ (2.6) C+ (2.8)
2026-10-17 B- (3.0) A- (4.1) C+ (2.5) C- (2.1) C+ (2.6) B- (2.9)
Page 1 of 3